IMpassion031: Efficacy, safety and patient (pts)-reported outcomes/quality of life (QoL) - Results from a Ph 3 study of neoadjuvant (neoadj) atezolizumab + chemo in early stage triple-negative breast cancer (eTNBC)

Artigo

Produção Nacional

IMpassion031: Efficacy, safety and patient (pts)-reported outcomes/quality of life (QoL) - Results from a Ph 3 study of neoadjuvant (neoadj) atezolizumab + chemo in early stage triple-negative breast cancer (eTNBC)

2021; Georg Thieme Verlag; Linguagem: Inglês

10.1055/s-0041-1730167

ISSN

1611-647X

Autores

Nadia Harbeck, H Zhang, CH Barrios, Shigehira Saji, Keun‐Hwa Jung, R. Hegg, A Köhler, Joohyuk Sohn, Hiroji Iwata, ML Telli, Cristiano Ferrario, Kevin Punie, Frédérique Penault‐Llorca, Salma Patel, Swayamprakash Patel, Anh Nguyen Duc, Mario Liste-Hermoso, Vidya Maiya, Luciana Molinero, SY Chui, EA Mittendorf,

Tópico(s)

Cancer Treatment and Pharmacology

Resumo

Background IMpassion031 is a randomised, placebo-controlled Ph3 study in high-risk primary invasive eTNBC evaluating neoadj atezolizumab (A) or placebo (P) with nab-paclitaxel (nP) followed by A or P with dose-dense doxorubicin + cyclophosphamide.

Ver no editor

Altmetric

PlumX

Entrar

Lembrar minha senha

Receber meu e-mail de confirmação

IMpassion031: Efficacy, safety and patient (pts)-reported outcomes/quality of life (QoL) - Results from a Ph 3 study of neoadjuvant (neoadj) atezolizumab + chemo in early stage triple-negative breast cancer (eTNBC)